Arrowhead Pharmaceuticals stock analysis
Arrowhead Pharmaceuticals (0HI3) Share Price & Analysis
0HI3 Stock Chart & Stats
- Day’s Range
- $42.41 - $45.00
- 52-Week Range
- $37.07 - $95.49
- Previous Close
- $44.79
- Volume
- N/A
- Average Volume (3M)
- 1,555
- Market Cap
- $6.08B
- Enterprise Value
- $9.46B
- Total Cash (Recent Filing)
- $1.19B
- Total Debt (Recent Filing)
- $1.00B
- Price to Earnings (P/E)
- ―
- Beta
- 1.27
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- -1.5
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Early Commercial Adoption And Payer Access
REDEMPLO is showing measurable early adoption through rising prescriptions, a growing prescriber base, and broadening payer coverage. These commercial foundations can support more durable product revenue as physician familiarity, reimbursement processes, and patient access improve over the next several quarters.
Strong SHTG Clinical Efficacy And Regulatory Progress
Consistent success across pivotal studies strengthens the clinical and regulatory case for plozasiran in severe hypertriglyceridemia. The combination of substantial lipid reduction and priority-review progress could support a meaningful commercial opportunity if approval and labeling are achieved.
Improved Debt Structure And Financing Flexibility
Refinancing materially improves the terms and maturity profile of Arrowhead's debt compared with the retired facility. Lower financing costs, no near-term scheduled amortization, and removal of cash-sweep requirements provide greater flexibility to fund development and commercialization activities.
Bears Say
Large Losses And Renewed Cash Burn
The return to substantial operating and free-cash-flow deficits shows that current activities are consuming capital faster than the business generates it. Persistent losses and spending needs may increase reliance on financing, limit strategic flexibility, and pressure liquidity before products scale.
Sharp Increase In Leverage And Reduced Balance-sheet Flexibility
The sharp increase in leverage leaves Arrowhead with less financial resilience while its operating results remain loss-making. A large debt burden relative to equity can constrain capital allocation, increase refinancing or dilution risk, and make future setbacks more difficult to absorb.
Commercial Conversion And Launch Execution Risk
Prescription growth has not yet translated automatically into paid treatment, because reimbursement and administrative steps remain necessary for each patient. Continued conversion friction could delay revenue scaling, raise commercialization demands, and weaken the pace at which market access becomes recurring sales.
Arrowhead Pharmaceuticals News
0HI3 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
What is Arrowhead Pharmaceuticals’s market cap?
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Is Arrowhead Pharmaceuticals overvalued?
Does Arrowhead Pharmaceuticals pay dividends?
What is Arrowhead Pharmaceuticals’s EPS estimate?
How many shares outstanding does Arrowhead Pharmaceuticals have?
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Arrowhead Pharmaceuticals Stock Smart Score
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher R. Anzalone
- Employees
- 1,059
- Website
- arrowheadpharma.com
- Address
- 177 East Colorado Boulevard, Pasadena, CA, 91105, US
Arrowhead Pharmaceuticals (0HI3) Earnings & Revenues
0HI3 Earnings Call
Earnings Call SentimentPositive
The call was predominantly optimistic, with strong REDEMPLO prescription and prescriber growth, broadening payer coverage, positive pivotal sHTG efficacy results, clinical validation of new RNAi delivery capabilities and improved financing terms. These positives were tempered by a substantial net loss, lower year-over-year revenue, higher operating expenses, ongoing prescription-to-paid-claim conversion work, regulatory and launch uncertainty for sHTG, glycemic-control findings and unresolved safety and dosing questions for ARO-DIMER-PA.
View all GB:0HI3 earnings summaries0HI3 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |










